A recent filing with the Securities and Exchange Commission detailed a transaction involving Altria Group, Inc. director Debra J. Kelly-Ennis. Ms. Kelly-Ennis sold shares of the company's common stock totaling approximately $418,317 on May 26, 2026. The specific disposition involved 5,790 shares.
According to the filing details, these shares were liquidated through several transactions, with individual sale prices ranging from $72.24 to $72.26 per share. This resulted in a weighted average selling price of $72.2483 per share. It is noteworthy that this divestiture took place near the stock's 52-week high of $74.56, following a period where the stock had achieved a strong gain of 27% year-to-date.
Beyond the insider selling activity, Altria Group has recently reported several significant corporate updates and operational changes that provide context to the company's current market standing. In terms of financial performance, the tobacco giant announced first-quarter adjusted earnings per share of $1.32. This figure notably surpassed the consensus estimate provided by analysts, which stood at $1.25. Additionally, the company reported revenue that exceeded expectations by 4%, and its gross margin outperformed forecasts by 90 basis points (bps). These strong metrics led to operating income coming in 5% above the consensus forecast.
Following this positive earnings release, institutional coverage was upgraded. Morgan Stanley revised its price target for Altria, raising it to $71 from a previous level of $62, while simultaneously maintaining an 'Equalweight' rating on the stock.
The company is also undergoing structural and leadership adjustments. Operationally, Altria announced plans to close its Nashville manufacturing facility. These operations will be consolidated at a new plant located in Hopkinsville, Kentucky, with management anticipating that this transition process will conclude by early 2028. On the governance front, Salvatore Mancuso was appointed as the Chief Executive Officer following the company's annual meeting. His compensation structure is comprehensive, encompassing a base salary of $1,350,000, in addition to stock units and long-term incentive plans.
Furthermore, Altria continues to manage its portfolio amidst evolving regulatory landscapes. The company was directly affected by recent FDA guidance concerning enforcement priorities for tobacco products. This updated guidance specifically pertains to both eVapour products and oral nicotine pouches that are currently under scientific review. These various developments illustrate the ongoing adjustments Altria is making in response to shifting market dynamics and regulatory pressures.
For investors analyzing Altria's valuation, the company maintains an attractive dividend yield of 5.88% and boasts a history of paying dividends for 56 consecutive years. Analysis from InvestingPro suggests that Altria appears undervalued at current pricing levels, positioning it among stocks identified as being highly undervalued.
As for Ms. Kelly-Ennis's remaining stake, following the recent sale, she continues to hold 73,809 shares of Altria Group common stock. These holdings include deferred stock that are managed within the Stock Compensation Plan designated for Non-Employee Directors.